相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Aaron N. Hata et al.
NATURE MEDICINE (2016)
Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma
Nadeera De Silva et al.
BRITISH JOURNAL OF CANCER (2015)
Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets
Evan Z. Macosko et al.
CELL (2015)
Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients
Rona Yaeger et al.
CLINICAL CANCER RESEARCH (2015)
Liquid biopsy: will it be the 'magic tool' for monitoring response of solid tumors to anticancer therapies?
Isabelle Gingras et al.
CURRENT OPINION IN ONCOLOGY (2015)
Stromal biology and therapy in pancreatic cancer: a changing paradigm
Albrecht Neesse et al.
GUT (2015)
Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non-Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses
Gideon M. Blumenthal et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Melissa L. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
Sara A. Hurvitz et al.
LANCET ONCOLOGY (2015)
On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients
Maria Schwaederle et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Therapy-induced tumour secretomes promote resistance and tumour progression
Anna C. Obenauf et al.
NATURE (2015)
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Luping Lin et al.
NATURE GENETICS (2015)
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer
Gorjan Hrustanovic et al.
NATURE MEDICINE (2015)
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna et al.
NATURE MEDICINE (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
Toward understanding and exploiting tumor heterogeneity
Ash A. Alizadeh et al.
NATURE MEDICINE (2015)
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
Hyo-eun C. Bhang et al.
NATURE MEDICINE (2015)
Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer
L. V. Sequist et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A New Initiative on Precision Medicine
Francis S. Collins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy
Gregory K. Behbehani et al.
CANCER DISCOVERY (2015)
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations
Leanne G. Ahronian et al.
CANCER DISCOVERY (2015)
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
Zofia Piotrowska et al.
CANCER DISCOVERY (2015)
NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer
Collin M. Blakely et al.
CELL REPORTS (2015)
Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
Ho-June Lee et al.
CANCER CELL (2014)
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Rakesh K. Jain
CANCER CELL (2014)
Organoid Cultures Derived from Patients with Advanced Prostate Cancer
Dong Gao et al.
CELL (2014)
Identification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures
Wouter R. Karthaus et al.
CELL (2014)
Targeted Therapies in Brain Metastases
Nancy U. Lin
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2014)
Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor
Douglas B. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Vemurafenib Oral Bioavailability: An Insoluble Problem
Russell Z. Szmulewitz et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 ( XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors
Pasi A. Jaenne et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Tumour heterogeneity and the evolution of polyclonal drug resistance
Rebecca A. Burrell et al.
MOLECULAR ONCOLOGY (2014)
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine
Eliezer M. Van Allen et al.
NATURE MEDICINE (2014)
Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture
Xingnan Li et al.
NATURE MEDICINE (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer REPLY
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Adam S. Crystal et al.
SCIENCE (2014)
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
Elza C. de Bruin et al.
SCIENCE (2014)
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
Judith Mueller et al.
NATURE COMMUNICATIONS (2014)
MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
Nikhil Wagle et al.
CANCER DISCOVERY (2014)
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Eliezer M. Van Allen et al.
CANCER DISCOVERY (2014)
Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine
Crispin Hiley et al.
GENOME BIOLOGY (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
Rizwan Haq et al.
CANCER CELL (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Muhammed Murtaza et al.
NATURE (2013)
Tumor adaptation and resistance to RAF inhibitors
Piro Lito et al.
NATURE MEDICINE (2013)
Evolutionary dynamics of cancer in response to targeted combination therapy
Ivana Bozic et al.
ELIFE (2013)
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
Piro Lito et al.
CANCER CELL (2012)
Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to Resistance
Elizabeth S. Nakasone et al.
CANCER CELL (2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy
Samir E. Witta et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman et al.
NATURE (2012)
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Timothy R. Wilson et al.
NATURE (2012)
Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA repair
Xue Zhang et al.
NATURE GENETICS (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
Levi A. Garraway et al.
CANCER DISCOVERY (2012)
Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations
Rafael Rosell et al.
CLINICAL CANCER RESEARCH (2011)
Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
Filip Janku et al.
PLOS ONE (2011)
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
Alexa B. Turke et al.
CANCER CELL (2010)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
Katharine A. Price et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Translating cancer research into targeted therapeutics
J. S. de Bono et al.
NATURE (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
Ten Years On -- The Human Genome and Medicine.
Harold Varmus
NEW ENGLAND JOURNAL OF MEDICINE (2010)
In Vivo Imaging in Cancer
John Condeelis et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Shifting paradigms: the seeds of oncogene addiction
Charles L. Sawyers
NATURE MEDICINE (2009)
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus
Gregory J. Riely et al.
CLINICAL CANCER RESEARCH (2007)
Pharmacokinetic variability of anticancer agents
SD Undevia et al.
NATURE REVIEWS CANCER (2005)
Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation
RB Boxer et al.
CANCER CELL (2004)
分享论文
